Daxor (DXR) stock rocketed higher on Thursday after the blood volume measurement technology company received clearance from the U.S. Food and Drug Administration (FDA) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). This new device measures a patient’s blood volume compared to patient-specific norms, allowing for precise fluid management.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Daxor Chief Medical Officer John Jefferies said, “By using the gold standard indicator tracer dilution technique, we can overcome the inaccuracies of traditional clinical assessments, especially in patients with multiple and complex conditions.”
Daxor Stock Movement Today
Daxor stock was up 21.9% in pre-market trading on Thursday, following a 0.3% rally yesterday. The shares were also up 30.04% year-to-date and 12.37% over the past 12 months. Today’s news brought heavy trading to DXR stock, with some 765,000 shares traded, compared to a three-month daily average of just 5,250 units.
Is Daxor Stock a Buy, Sell, or Hold?
Turning to Wall Street, coverage of Daxor is thin. However, TipRanks’ AI analyst Spark has it covered. Spark rates DXR stock a Neutral (55) with no price target. It cites “mixed performance,” including a positive earnings call and operational challenges, as reasons for this stance.
